Wave Life Sciences Ltd.
NASDAQ:WVEBiotechnology
+$0.10 today
- Market cap
- $536.46M
- Beta
- -1.33
- P/E (TTM)
- -6.6
- EPS (TTM)
- -$0.92
Volume 1.92M
Average 4.86M
Income Statement
Follow revenue through to earnings.
Revenue
$42.73M
FY 2025 · Annual
-60.5% YoYOperating Income
-$215.38M
FY 2025 · Annual
Net Income
-$204.38M
FY 2025 · Annual
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 40.96M | 3.65M | 113.31M | 108.3M | 42.73M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 8.85M |
| Gross Profit | 40.96M | 3.65M | 113.31M | 108.3M | 33.88M |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 79.3% |
| Research & Development | 121.88M | 115.86M | 130.01M | 159.68M | 182.78M |
| Selling, General & Admin | 46.11M | 50.51M | 51.29M | 59.02M | 75.33M |
| Operating Expenses | 167.98M | 166.37M | 181.3M | 218.71M | 249.26M |
| Depreciation & Amortization | 9.84M | 10.11M | 9.21M | 8.66M | 8.85M |
| EBITDA | (112.61M) | (151.03M) | (48.98M) | (88.35M) | (195.53M) |
| EBITDA Margin | -274.9% | -4138.9% | -43.2% | -81.6% | -457.6% |
| Operating Income | (127.02M) | (162.72M) | (68M) | (110.4M) | (215.38M) |
| Operating Margin | -310.1% | -4459.3% | -60.0% | -101.9% | -504.1% |
| Interest Income | 30K | 0 | 0 | 0 | 10.48M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 4.57M | 1.58M | 9.81M | 13.4M | 11.01M |
| Income Before Tax | (122.45M) | (161.14M) | (58.19M) | (97.01M) | (204.38M) |
| Pre-Tax Margin | -298.9% | -4416.1% | -51.4% | -89.6% | -478.3% |
| Income Tax Expense | (204K) | 681K | (677K) | 0 | 0 |
| Net Income | (122.25M) | (161.82M) | (57.51M) | (97.01M) | (204.38M) |
| Net Margin | -298.4% | -4434.7% | -50.8% | -89.6% | -478.3% |
| EPS (Basic) | (2.36) | (2.05) | (0.54) | (0.70) | (1.21) |
| EPS (Diluted) | (2.36) | (2.05) | (0.54) | (0.70) | (1.21) |
| 51.83M | 78.86M | 106.1M | 138.28M | 168.65M | |
| 51.83M | 78.86M | 106.1M | 138.28M | 168.65M |
WVE Earnings Waterfall · TTM
NASDAQ:WVE · Revenue to Net Income
Key Ratios
Analysis
$71.8M of revenue converted into -$183.6M of net income for the selected period. Gross margin is 90.4% and net margin is -416.1%, showing how much revenue survives after costs and taxes. EPS is $-1.06, tying the income statement back to per-share earnings.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| SC 13G | SC 13G filing | Oct 27, 2026 | |
| 8-K | Current report | Oct 27, 2026 | |
| 10-Q | Quarterly report | Oct 27, 2026 | |
| SC 13G/A | SC 13G/A filing | Oct 27, 2026 | |
| ARS | ARS filing | Oct 14, 2026 |
How much revenue does WVE generate?
Wave Life Sciences Ltd. (WVE) reported $42.73M of revenue in fiscal 2025.
Is WVE profitable?
Wave Life Sciences Ltd. (WVE) reported -$204.38M of net income, with a net margin of -478.3%.
Continue the stock analysis
Jump to another research area for this company.